The Peptide Buyer’s Guide for Men Over 40: What You’re Actually Risking, Compound by Compound

Right, let’s talk straight. You wouldn’t buy a nail gun off a bloke in a lay-by with no box, no manual, and no idea what’s actually in the cartridge. But that’s exactly what a lot of men over 40 are doing with peptides, and the sales pages selling them to you spend one line on the risks and three paragraphs on the dream. This guide flips that ratio. Every claim below links back to the actual source, because when it’s going into your body, you check the paperwork yourself, you don’t take some stranger’s word for it.

Think of this like reading the safety sheet before you use a bit of kit you’ve never handled. Not to put you off. So you know exactly where the sharp edges are before you pick it up.

Two risks that come free with everything on this list

Before we get into individual compounds, there are two hazards that sit underneath the whole category. Doesn’t matter which vial you’re holding, you’re carrying both.

First one: the product itself. Buy from a research-chemical site and what turns up is stamped “for research use only, not for human consumption.” That’s not small print for show, that’s the legal loophole that lets them sell it to you at all. It also means nobody has checked that vial for identity, strength, purity, or contamination. No warranty, no manufacturer standing behind the product, no recall line to ring if something’s wrong. You’re trusting the seller’s word and nothing else. The peptide could be underdosed, overdosed, mislabeled, or cut with something you never ordered, and if it goes wrong, there’s no one accountable. That’s the single biggest risk on this whole page, and it sits under every compound listed below.

Second one: the screening you’re skipping. A fair few of these compounds have risks that only surface once someone qualified has looked at your history and your bloods. Buy it yourself and skip that step, and you’re betting none of the hidden risk factors apply to you, with nobody checking your work.

Keep both of those in your back pocket. They colour everything that follows.

Testosterone: best paperwork, clearest warning label

Start here because testosterone is the anchor product in this whole category, it gets bundled in with the peptides constantly, and it’s got more evidence behind it than anything else on this list. That cuts two ways. You can trust the upside more. You also can’t wave off the downside, because it was measured properly, in thousands of men.

The big study is TRAVERSE, published in the New England Journal of Medicine in 2023. It put 5,246 middle-aged and older men with diagnosed low testosterone plus cardiovascular risk on testosterone gel or placebo, and found testosterone didn’t raise major cardiac events versus placebo, which was the safety test it needed to pass [1]. That’s a genuinely good result after years of heart worry. But read the whole report, not just the headline, because it also flagged more cases of atrial fibrillation, an irregular heartbeat, in the men on testosterone [1].

What that means for you, plainly: testosterone isn’t a free upgrade you bolt on. If you’ve got an undiagnosed rhythm problem in your heart, this is exactly the sort of thing that can bring it out into the open, and you’d have no way of catching that on your own. That’s why it’s a prescription medicine, and why it comes with monitoring attached. The support drugs men run alongside it, HCG, enclomiphene, anastrozole, exist to manage what testosterone does to fertility and estrogen, and they’re prescription too [2]. Testosterone isn’t the danger here. Testosterone with no one checking your heart first is.

Growth-hormone peptides: strong tools, thin instructions

Next up, the growth-hormone-releasing group: sermorelin, CJC-1295, ipamorelin. Different risk story to testosterone. It’s not a pile of documented harm. It’s genuinely potent pharmacology paired with a safety manual that’s about two pages long.

Take CJC-1295. A 2006 study gave healthy adults one injection and watched growth hormone climb 2- to 10-fold, with IGF-1 staying up for nine to eleven days [3]. Sit with that. One dose, and a powerful hormone stays elevated for over a week. That’s serious, well-documented pharmacology, and it’s exactly why you don’t wing the dose. Push GH and IGF-1 too far and you’re into territory with its own problems, and you’d be finding the edge of that territory by trial and error, because there’s no proper human dosing map to follow.

Ipamorelin’s the other half of the picture. Its most rigorous human trial, randomised and placebo-controlled, from 2014, found it well tolerated but it didn’t beat placebo on its main goal, missing the target it was tested against (p = 0.15) [4]. Two takeaways. “Well tolerated” is mildly reassuring on short-term safety. “Missed the target” tells you the payoff you’re taking the risk for might be smaller than the marketing implies, and that changes the whole cost-benefit sum.

Honest read on this group: potent, thin human safety data mostly over the short term, none of it FDA-approved for anti-aging or performance use. Your protection here isn’t a dose you copied off a forum thread. It’s a clinician who can adjust the dose to your body and actually watch what happens.

BPC-157: the compound with no spec sheet at all

If you only remember one warning off this page, make it this one. BPC-157 is the recovery peptide your gym mates won’t shut up about, and it’s the clearest case of the marketing running way past the paperwork.

A 2025 systematic review in the journal of the Hospital for Special Surgery went through the BPC-157 research and found nearly all of it is preclinical, meaning animals and lab cells, with no clinical safety data in humans, no FDA-approved use, and risks tied to unregulated production on top [5]. Read that again. The tendon-healing stories doing the rounds trace back to rats. There’s no human safety file. No agreed dose, no documented side-effect list in people, nobody vouching for what’s actually in the vial you’d be buying.

You should also know the legal status is moving, because sellers will spin this at you hard. BPC-157 was on the FDA’s Category 2 “do not compound” list, then in April 2026 it was removed along with eleven other peptides after the nominations were withdrawn, with a Pharmacy Compounding Advisory Committee due to meet 23 to 24 July 2026 to decide whether it belongs on the approved compounding list [6]. Don’t let anyone sell you “taken off the banned list” as “cleared and safe.” It’s not the same thing. It’s in a holding pattern while a federal committee makes up its mind, and that does nothing to fill the human safety gap the science already flagged. Bottom line: with BPC-157, the ground you’d normally stand on, actual human safety data, just isn’t there. If you go near it at all, doing it without a clinician who knows your full history is the riskiest move on this whole page.

NAD+ precursors: the gentle option, still oversold

Not everything here is a live wire, and you deserve the good news too. NAD+ precursors have the mildest risk profile on this list, though there are still edges worth knowing.

NAD+ is a coenzyme your cells use for energy and repair, and it drops off with age. Since NAD+ itself is awkward to dose as a pill, most of the human research is on precursors like nicotinamide riboside. A 2018 randomised, double-blind, placebo-controlled trial gave nicotinamide riboside to healthy middle-aged and older adults and found it well tolerated, and it did raise NAD+ levels in the blood [7]. That’s a genuinely encouraging short-term safety result for that particular pill.

Now the edges. “Well tolerated over the study period” isn’t the same claim as “proven safe for years of use,” and it’s definitely not proof it reverses aging, which the trial never said anyway [7]. Also worth knowing: NAD+ given by injection or IV is a different, less-studied route than the oral tablet that trial actually tested. The reassuring data doesn’t automatically transfer over to a needle. So your risk here is lower than everywhere else on this page, but not zero, and the promises are running well past what the evidence actually backs.

The risk with nothing to do with side effects

Here’s a hazard that can bite you even if the compound itself never does, and it catches men over 40 out constantly because they assume it’s only a problem for pros. Compete in anything tested, even masters-level amateur racing, lifting, or a league with drug testing, and the anti-doping rules apply to you the same as anyone else.

Under the 2026 WADA Prohibited List, peptide hormones, growth factors, and growth-hormone secretagogues sit under class S2 and are banned in sport, and testosterone is banned too [8]. That sweeps up sermorelin, CJC-1295, ipamorelin, the whole group. And here’s the bit that trips men up: a “research use only” label gives a tested athlete zero cover. Banned is banned, regardless of what the label calls it or how you got hold of it. So if you compete, the risk you’re weighing isn’t just a side effect. It’s a failed test and every consequence that comes after it.

So which tool do you actually reach for?

Step back and the pattern’s obvious. These risks aren’t one blob, and treating them like they are is how blokes get hurt. Testosterone has real, measured risks like atrial fibrillation that need monitoring [1]. The growth-hormone peptides are strong tools with a thin instruction manual, so dose discipline is everything [3]. BPC-157 has next to no human safety data, and that’s its own category of risk entirely [5]. NAD+ precursors are the mildest but still oversold [7]. And underneath all of it sits the unverified-product risk and the anti-doping risk, no matter which one you pick.

Notice what fixes most of these at once: a qualified person actually looking at your situation. A clinician checks your heart before testosterone. Doses the growth-hormone peptides to your body rather than a number off a forum. Tells you straight that BPC-157’s safety file is basically empty. Asks if you compete before you end up flagged. And a licensed pharmacy is accountable for what’s genuinely in the vial, which is the warranty you don’t get from a research-chemical website.

That’s the real difference in this category: managed risk versus blind risk. If you want the model built the right way round, where a licensed clinician assesses you and writes a prescription when it’s warranted, and a licensed pharmacy fills it, FormBlends is one such physician-supervised path among the supervised options out there. There’s nothing for sale here and no checkout to click through, this isn’t a shop window. The name isn’t the point. The structure underneath it is. In a category this uneven, the oversight isn’t a nice-to-have bolted on afterward. It’s the whole safety mechanism.

None of this tells you whether you personally should take any of it. That call is yours and your clinician’s, once they’ve seen your numbers. This was just the hazard sheet, laid out straight, for a bloke who’d rather know what he’s buying before he buys it.

Common questions

What’s the single biggest risk in buying peptides for men over 40? The unverified product itself. Vials labeled “for research use only” haven’t been checked for identity, strength, purity, or contamination, so what’s inside can be underdosed, overdosed, mislabeled, or cut with something else entirely, and there’s no recall authority standing behind it. That supply risk sits under every individual compound and outranks any single side effect you’d worry about.

Does the TRAVERSE trial mean testosterone is safe for men over 40? It answers one specific question well, it’s not a blanket all-clear. TRAVERSE randomised 5,246 men with diagnosed low testosterone plus cardiovascular risk and found testosterone didn’t raise major cardiac events versus placebo, but the same trial recorded more cases of atrial fibrillation in the men taking it. The practical read: testosterone done properly is a monitored process, which is why a clinician should check your heart and bloodwork before you start.

Is BPC-157 safe now the FDA took it off the “do not compound” list? No. The April 2026 removal moved it into a holding pattern while a Pharmacy Compounding Advisory Committee meets 23 to 24 July 2026 to decide whether it belongs on the approved list. Removed isn’t approved, and it does nothing to fill the human safety gap flagged by a 2025 systematic review that found nearly all BPC-157 research is preclinical, with no clinical safety data in people.

Are sermorelin, CJC-1295, and ipamorelin dangerous? The issue isn’t a stack of documented harm, it’s strong pharmacology paired with a thin human safety file. CJC-1295 can keep IGF-1 elevated for nine to eleven days off a single dose, and none of these growth-hormone peptides is FDA-approved for anti-aging or athletic use, so dose discipline from a clinician matters far more than a number pulled off a forum.

Are NAD+ precursors the safer option? They’ve got the mildest risk profile here, but there are edges. A 2018 trial found oral nicotinamide riboside well tolerated and able to raise blood NAD+ in middle-aged and older adults, but “well tolerated over the study period” isn’t “proven safe for years,” and that oral data doesn’t automatically carry over to injection or IV routes, which are far less studied.

Can taking these peptides get me flagged in a tested competition? Yes, even at masters or amateur level. Under the 2026 WADA Prohibited List, peptide hormones, growth factors, and growth-hormone secretagogues fall under class S2 and are banned in sport, and testosterone is banned too. A “research use only” label gives a tested athlete no cover whatsoever, since a banned substance stays banned no matter what the bottle says on it.

References

1. Lincoff AM, et al. “Cardiovascular Safety of Testosterone-Replacement Therapy” (TRAVERSE). N Engl J Med. 2023 (n=5,246; noninferior for MACE; more atrial fibrillation in the testosterone group). https://pubmed.ncbi.nlm.nih.gov/37326322/
2. “Glucagon-Like Peptide-1 Receptor Agonists.” StatPearls, NCBI Bookshelf (boxed-warning context illustrating why prescription oversight and monitoring matter for hormone and peptide therapies). https://www.ncbi.nlm.nih.gov/books/NBK551568/
3. Teichman SL, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” J Clin Endocrinol Metab. 2006.
4. Beck DE, et al. “Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.” Int J Colorectal Dis. 2014 (missed primary endpoint, p = 0.15).
5. Vasireddi N, et al. “Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.” HSS Journal. 2025 (mostly preclinical; no clinical safety data; no FDA-approved indication).
6. Frier Levitt. “FDA Peptide Update 2026: Removal from ‘Do Not Compound’ List and What It Means for Pharmacies” (BPC-157 removed from Category 2 in April 2026; PCAC review July 23 to 24, 2026; removal is not approval).
7. Martens CR, et al. “Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults.” Nat Commun. 2018.
8. USADA. “2026 WADA Prohibited List” (S2: peptide hormones, growth factors, and GH secretagogues prohibited in sport).